We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic's (MDT) Midas Rex Drills Completes First U.S. Surgery
Read MoreHide Full Article
Medtronic plc (MDT - Free Report) announced successful run of the first U.S. minimally invasive spinal procedures using the newly cleared navigated disc prep, interbodies and Midas Rex high speed drills with the Mazor Robotic Guidance System. This latest achievement is a major breakthrough in the transformative process of spine surgery as a result of increased precision and minimally invasive technique.
With this feat, Medtronic will boost its Restorative Therapies Group segment.
More in the News
Per Dr. Gregory Poulter, the first to complete the above-mentioned procedure, robotic guidance is beneficial in lumbar spine procedure and has a life-changing potential.
Dr. Sharad Rajpal who was the second person to conduct the surgery on an 83-year-old male suffering back and severe progressive leg pain and weakness (that prevented him from walking) happily informed that the patient is already discharged from the hospital and is recovering at home with minimal pain.
The third surgery was performed by Dr. Eiman Shafa on a 36-year-old male with severe left lower extremity pain. Medtronic claims that post surgery, the patient was relieved from radicular leg pain.
Significance of Mazor Robotic Guidance System
Per Dr. Rajpal, this latest technology allows surgeons to perform spinal procedures more effectively through concise planning and execution in the operating room.
Mazor Robotic Guidance System can be easily integrated by surgeons into their workflows. The newest software update and instrumentation sets also help improve workflow significantly, providing a more insightful interface for surgeons during the planning phase as well as more streamlined steps while execution.
Industry Prospects
Per Reports and Data, the global surgical robotics and navigation market was $1.94 billion in 2019 and is expected to reach $9.47 billion by 2027, seeing a CAGR of 21.7%. The rise in demand for minimally invasive surgeries among patients and the introduction of advanced medical systems are the key catalysts for the market.
Notable Developments
In February 2021, management announced the early site release of the company’s new radial artery access portfolio. The Rist Radial Access portfolio gives clinicians the full spectrum of access and delivery devices that are optimized for the patient's condition and anatomy.
In January 2021, Medtronic gets the FDA nod for DiamondTem Ablation system, which treats patients with recurrent, symptomatic paroxysmal atrial fibrillation and an unresponsive history to drug therapy. With this regulatory approval, Medtronic continues to drive clinical research and innovation to find differentiated solutions for those in the front line of patient care.
Price Performance
Shares of the company have gained 3.9% in a year’s time compared with the industry’s growth of 9.4%.
Zacks Rank and Key Picks
Currently, Medtronic carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Meridian Bioscience Inc. , Abbott Laboratories (ABT - Free Report) and Apyx Medical Corporation (APYX - Free Report) . While Meridian Bioscience sports a Zacks Rank #1 (Strong Buy), both Abbott Laboratories and Apyx Medical carry a Zacks Rank #2 (Buy) at present. You can see the complete list of Zacks #1 Rank stocks here.
Meridian Bioscience has a projected long-term earnings growth rate of 70%.
Abbott Laboratories has a projected long-term earnings growth rate of 14%.
Apyx Medical has an estimated long-term earnings growth rate of 28%.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Image: Shutterstock
Medtronic's (MDT) Midas Rex Drills Completes First U.S. Surgery
Medtronic plc (MDT - Free Report) announced successful run of the first U.S. minimally invasive spinal procedures using the newly cleared navigated disc prep, interbodies and Midas Rex high speed drills with the Mazor Robotic Guidance System. This latest achievement is a major breakthrough in the transformative process of spine surgery as a result of increased precision and minimally invasive technique.
With this feat, Medtronic will boost its Restorative Therapies Group segment.
More in the News
Per Dr. Gregory Poulter, the first to complete the above-mentioned procedure, robotic guidance is beneficial in lumbar spine procedure and has a life-changing potential.
Dr. Sharad Rajpal who was the second person to conduct the surgery on an 83-year-old male suffering back and severe progressive leg pain and weakness (that prevented him from walking) happily informed that the patient is already discharged from the hospital and is recovering at home with minimal pain.
The third surgery was performed by Dr. Eiman Shafa on a 36-year-old male with severe left lower extremity pain. Medtronic claims that post surgery, the patient was relieved from radicular leg pain.
Significance of Mazor Robotic Guidance System
Per Dr. Rajpal, this latest technology allows surgeons to perform spinal procedures more effectively through concise planning and execution in the operating room.
Mazor Robotic Guidance System can be easily integrated by surgeons into their workflows. The newest software update and instrumentation sets also help improve workflow significantly, providing a more insightful interface for surgeons during the planning phase as well as more streamlined steps while execution.
Industry Prospects
Per Reports and Data, the global surgical robotics and navigation market was $1.94 billion in 2019 and is expected to reach $9.47 billion by 2027, seeing a CAGR of 21.7%. The rise in demand for minimally invasive surgeries among patients and the introduction of advanced medical systems are the key catalysts for the market.
Notable Developments
In February 2021, management announced the early site release of the company’s new radial artery access portfolio. The Rist Radial Access portfolio gives clinicians the full spectrum of access and delivery devices that are optimized for the patient's condition and anatomy.
In January 2021, Medtronic gets the FDA nod for DiamondTem Ablation system, which treats patients with recurrent, symptomatic paroxysmal atrial fibrillation and an unresponsive history to drug therapy. With this regulatory approval, Medtronic continues to drive clinical research and innovation to find differentiated solutions for those in the front line of patient care.
Price Performance
Shares of the company have gained 3.9% in a year’s time compared with the industry’s growth of 9.4%.
Zacks Rank and Key Picks
Currently, Medtronic carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Meridian Bioscience Inc. , Abbott Laboratories (ABT - Free Report) and Apyx Medical Corporation (APYX - Free Report) . While Meridian Bioscience sports a Zacks Rank #1 (Strong Buy), both Abbott Laboratories and Apyx Medical carry a Zacks Rank #2 (Buy) at present. You can see the complete list of Zacks #1 Rank stocks here.
Meridian Bioscience has a projected long-term earnings growth rate of 70%.
Abbott Laboratories has a projected long-term earnings growth rate of 14%.
Apyx Medical has an estimated long-term earnings growth rate of 28%.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>